G J van Steenbrugge

Author PubWeight™ 50.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998 2.10
2 In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate 1995 2.07
3 Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst 2000 1.78
4 Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992 1.64
5 Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996 1.29
6 Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999 1.16
7 Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 1997 1.11
8 Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 1993 1.05
9 EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 2000 0.99
10 Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 2001 0.98
11 Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol 1990 0.98
12 Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate 1993 0.97
13 The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997 0.94
14 Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000 0.94
15 Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1996 0.92
16 Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003 0.92
17 Neutrons and X-rays, comparative studies with Drosophila melanogaster. 1. The viability and fertility of induced autosomal translocations. Mutat Res 1981 0.91
18 Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer 1999 0.90
19 Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981 0.90
20 Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol 1997 0.89
21 The use of steroid-containing Silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. Prostate 1984 0.88
22 Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res 1995 0.87
23 Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000 0.87
24 Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J Natl Cancer Inst 1987 0.87
25 Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985 0.87
26 The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Br J Cancer 2001 0.86
27 The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995 0.86
28 Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest 2000 0.86
29 Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 1999 0.86
30 Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression. Int J Cancer 1999 0.86
31 Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999 0.86
32 Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice. J Urol 1991 0.86
33 Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995 0.84
34 Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma. J Urol 1991 0.84
35 Immunohistochemical evaluation of the expression of prostate tumor-association markers in the nude mouse human prostate carcinoma heterotransplant lines PC-82, PC-EW, and PC-EG. Prostate 1990 0.82
36 Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 2000 0.81
37 Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82). J Urol 1984 0.81
38 Effects of adrenal androgens on the transplantable human prostate tumor PC-82. Endocrinology 1992 0.81
39 The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. J Urol 1997 0.81
40 Administration of an LHRH-antagonist to male mice: effects on in vivo secretion of hormones and on the growth of a transplantable human prostatic carcinoma. Life Sci 1987 0.80
41 Progress of fundamental research in Wilms' tumor. Urol Res 1997 0.79
42 Recent advances in the development of animal and cell culture models for prostate cancer research A minireview. Urol Oncol 2011 0.79
43 Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif 1993 0.78
44 Human prostate cancer (PC-82) in nude mice: a model to study androgen regulated tumor growth. Prog Clin Biol Res 1985 0.78
45 Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82. Endocrinology 1992 0.77
46 Characterization of androgen receptors after photoaffinity labelling with [3H]methyltrienolone (R1881). J Steroid Biochem 1986 0.77
47 Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urol Res 1992 0.77
48 Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines. Urol Res 1999 0.77
49 Characterization of androgen receptors in a transplantable human prostatic adenocarcinoma (PC-82). Prostate 1987 0.77
50 Expression of HLA-like structures on a permanent human tumor line PC-93. Tissue Antigens 1983 0.76
51 The cytocidal effect of high energy shock waves on human prostatic tumour cell lines. Eur J Cancer Clin Oncol 1989 0.76
52 Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. Prostate 1995 0.76
53 Hormone receptors in human prostate cancer. Scand J Urol Nephrol Suppl 1988 0.75
54 Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma. Urol Res 1996 0.75
55 A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells. Eur J Cancer 2001 0.75
56 Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines. Urol Res 1991 0.75
57 In vivo administration of a GnRH antagonist to male mice: effects on pituitary gonadotropin secretion in vitro. Acta Endocrinol (Copenh) 1989 0.75
58 Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anticancer Res 2002 0.75
59 Peptidylglycine alpha-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate. Int J Cancer 2001 0.75
60 Identification of a homozygous deletion at 8p12-21 in a human prostate cancer xenograft. Genes Chromosomes Cancer 1999 0.75
61 Human prostate tumor xenografts as representative models for clinical prostate cancer. Urol Oncol 2011 0.75
62 Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630). Urol Res 1984 0.75